FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
Evidence for efficacy is based on the results from the TIVO-3 study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Evidence for efficacy is based on the results from the TIVO-3 study
Clinical utility of whole-genome sequencing demonstrated for the genomic evaluation of patients with acute myeloid leukaemia or myelodysplastic syndromes
FDA also approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic for lorlatinib
Phase II randomised study met prespecified primary endpoint threshold in patients with operable non-small cell lung cancer
Abiraterone Accord is a generic of Zytiga, which has been authorised in the EU since 2011
Results of CheckMate 9ER study in patients with previously untreated advanced clear cell renal-cell carcinoma
Combination of cabozantinib and nivolumab is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma
Substantial antitumour activity observed with idecabtagene vicleucel in the KarMMa study
Twice daily poziotinib dosing improved the adverse event profile; early results showed retained anti-tumour activity
Clinical benefit of FGFR inhibition is stronger in patients with an FGFR fusion or mutation compared to FGFR amplification
Endogenous and exogenous mutational processes driven by abnormal DNA editing, mutagens or age-related DNA alterations over the history of a malignant tumour provide an individual tumour signature
Prelliminary data with IL-12 mRNA administered by intratumoural injection in combination with intravenous durvalumab
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.